Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 1.00 |
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.91 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | MPI | P34949 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | DDO | Q99489 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754183 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL12204302 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL5307307 | 0.91 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL10050059 | 0.84 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL3284596 | 0.84 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL15338397 | 0.83 | RAB9A (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29722594 | 0.83 | RAB9A (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL1900540 | 0.82 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL19841047 | 0.78 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL27691174 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710926-A1 | TOPICAL COMPOSITION | Api Co., Ltd. (JP) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024237182-A1 | TOPICAL COMPOSITION | アピ株式会社 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024237181-A1 | TOPICAL COMPOSITION | アピ株式会社 | 2024-11-21 | — | — | WO | disclosed |
| US-9724312-B2 | Agent for the prevention, improvement or treatment of retinal disease | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160136275-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160089345-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2016-03-31 | — | — | US | disclosed |
| US-20150025154-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20140350119-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ROHTO PHARMA (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140243419-A1 | MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140128475-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20140045948-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20130331458-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-12 | — | — | US | disclosed |
| US-20130303627-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303625-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303624-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303626-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128475-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ALDH1A2, ALDH1A3, PDE6D | KDM4E 3620/4885ALDH1A1 155/4885HPGD 71/4885 |
| US-20140243419-A1 | MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE | ALDH1A2, AGER, GLA | KDM4E 4805/4885ALDH1A1 522/4885HPGD 16/4885 |
| US-20150025154-A1 | OPHTHALMIC COMPOSITION | GSTO1, GSTK1, GSTA1 | KDM4E 4561/4885ALDH1A1 342/4885HPGD 34/4885 |
| US-20130331458-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | KDM4E 2184/4885ALDH1A1 1296/4885HPGD 488/4885 |
| US-20140045948-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | KDM4E 2184/4885ALDH1A1 1296/4885HPGD 488/4885 |
| US-20160089345-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | KDM4E 2184/4885ALDH1A1 1296/4885HPGD 488/4885 |
| US-20130303627-A1 | OPHTHALMIC COMPOSITION | GSTO1, GSTK1, GSTA1 | KDM4E 4561/4885ALDH1A1 342/4885HPGD 34/4885 |
| US-20130303625-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ALDH1A2, ALDH1A3, PDE6D | KDM4E 3620/4885ALDH1A1 155/4885HPGD 71/4885 |
| US-20160136275-A1 | OPHTHALMIC COMPOSITION | PLPBP, CRYAA, CRYAB | KDM4E 4738/4885ALDH1A1 2964/4885HPGD 66/4885 |
| US-20130303624-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ALDH1A2, PDE6C, PTGER3 | KDM4E 2395/4885ALDH1A1 137/4885HPGD 33/4885 |
| US-20130303626-A1 | OPHTHALMIC COMPOSITION | PLPBP, CRYAA, CRYAB | KDM4E 4738/4885ALDH1A1 2964/4885HPGD 66/4885 |
| US-20140350119-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ALDH1A2, PDE6C, PTGER3 | KDM4E 2395/4885ALDH1A1 137/4885HPGD 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.